🇺🇸 FDA
Pipeline program

HLX02

HLX02-BC01

Phase 3 mab completed

Quick answer

HLX02 for Breast Cancer is a Phase 3 program (mab) at Shanghai Henlius Biotech with 1 ClinicalTrials.gov record(s).

Program details

Company
Shanghai Henlius Biotech
Indication
Breast Cancer
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials